ProAxsis

ProAxsis is a UK-based diagnostics company focused on the respiratory disease market. Its core innovation is the ProteaseTag® platform, which enables the specific detection of active protease enzymes, offering a potential 'gold standard' over traditional assays that measure total protein. The company has commercialized several immunoassays and offers contract services, positioning itself as a partner for pharmaceutical development and clinical research in conditions like COPD and cystic fibrosis. It is a portfolio company of the investment group NetScientific plc.

Proprietary ProteaseTag® molecules that irreversibly and selectively bind to the active site of target proteases, enabling their specific detection in immunoassays (ELISA) and lateral flow point-of-care tests.

ProAxsis competes in the niche of protease activity detection. Competition includes large diagnostic companies (e.g., Roche, Abbott) offering standard ELISA kits for total protease protein, and research-focused biotech firms developing alternative activity-based probes. Its key differentiator is the patented specificity of the ProteaseTag® for the active enzyme form, which is not a feature of most commercially available assays.